Galderma Highlights Sustained Improvements with Nemluvio® (nemolizumab) for Atopic Dermatitis at EADV 2026

Galderma presented new data at the European Academy of Dermatology and Venereology (EADV) 2026 Congress, demonstrating sustained improvements for up to three years with Nemluvio® (nemolizumab) in patients with moderate-to-severe atopic dermatitis. Nemluvio, an IL-13Rα1-IL4Rα heterodimer inhibitor, is already approved in over 40 countries for atopic dermatitis and prurigo nodularis, and these long-term findings reinforce its efficacy and safety profile.